{
    "Disease activity (follow up: 1 year; assessed with: ACR 20)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "b"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["184/292 (63.0%)", "c"],
            "MTX monotherapy": "164/287 (57.1%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.10 (0.97 to 1.26)",
            "Absolute (95% CI)": "57 more per 1,000 (from 17 fewer to 149 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 1 year; assessed with: ACR 50)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["145/292 (49.7%)", "c"],
            "MTX monotherapy": "117/287 (40.8%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.22 (1.02 to 1.46)",
            "Absolute (95% CI)": "90 more per 1,000 (from 8 more to 188 more)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 1 year; assessed with: ACR 70)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "b"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["107/292 (36.6%)", "c"],
            "MTX monotherapy": "84/287 (29.3%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.25 (0.99 to 1.58)",
            "Absolute (95% CI)": "73 more per 1,000 (from 3 fewer to 170 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values –> benefit) (MCID -1.17)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "b"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["292", "c"],
            "MTX monotherapy": "287"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.96 lower (1.24 lower to 0.68 lower)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    },

    "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
        "IL-6i": ["115/292 (39.4%)", "c"],
        "MTX monotherapy": "56/287 (19.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 2.02 (1.53 to 2.66)",
            "Absolute (95% CI)": "199 more per 1,000 (from 103 more to 324 more)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "CRITICAL"
    },

    "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values –> benefit) (MCID 4.6)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["275", "c"],
            "MTX monotherapy": "267"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.88 lower (1.44 lower to 0.32 lower)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "IMPORTANT"
    },

    "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["0", "c"],
            "MTX monotherapy": "0"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.03 lower (0.15 lower to 0.09 higher)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "IMPORTANT"
    },

    "Quality of life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["0", "c"],
            "MTX monotherapy": "0"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.14 higher (0.13 lower to 0.41 higher)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "IMPORTANT"
    },

    "Quality of life (1 year) (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["0", "c"],
            "MTX monotherapy": "0"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.34 higher (0.68 lower to 1.36 higher)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "IMPORTANT"
    },

    "Serious adverse events (follow up: 1 year)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["25/292 (8.6%)", "c"],
            "MTX monotherapy": "24/282 (8.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.01 (0.59 to 1.72)",
            "Absolute (95% CI)": "1 more per 1,000 (from 35 fewer to 61 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Withdrawal due to lack of efficacy (follow up: 1 year)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "e"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["34/292 (11.6%)", "c"],
            "MTX monotherapy": "21/282 (7.4%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.56 (0.93 to 2.63)",
            "Absolute (95% CI)": "42 more per 1,000 (from 5 fewer to 121 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Death (follow up: 1 year)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["1/292 (0.3%)", "c"],
            "MTX monotherapy": "2/282 (0.7%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.48 (0.04 to 5.30)",
            "Absolute (95% CI)": "4 fewer per 1,000 (from 7 fewer to 30 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (follow up: 1 year)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["2/292 (0.7%)", "c"],
            "MTX monotherapy": "3/282 (1.1%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.64 (0.11 to 3.82)",
            "Absolute (95% CI)": "4 fewer per 1,000 (from 9 fewer to 30 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Myocardial infarction (follow up: 1 year)": {
        "No of studies": "9",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "f"],
        "Other considerations": "none",
        "Nº of patients": {
            "IL-6i": ["1/292 (0.3%)", "c"],
            "MTX monotherapy": "0/282 (0.0%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 2.90 (0.12 to 70.83)",
            "Absolute (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (from SRs of harms)": {
        "No of studies": "8",
        "content": "The Systematic Review RefID=1220, 2017 (RCTs=4) comparing abatacept vs placebo +csDMARD among RA showed that for cancer, the result was OR=1.12 (0.33, 3.81)."
    },

    "Serious adverse events (from SRs of harms)": {
        "No of studies": "10",
        "content": "The systematic review RefID=18, 2018 (RCTs=2, n=785) comparing IL-6 inhibitors vs MTX among TCZ naïve RA patients showed that for serious adverse events, the result was RR=2.57 (95% 0.61-10.93, p=0.2)."
    }
}